ZEB2 and malignant colon neoplasm: In addition to exploring the implications of the histone modification pattern on colon cancer treatment strategies, we also performed a genome-wide CRISPR screen and identified that ZEB2 is a potential driver gene contributing to the drug resistance in the background of histone modification alterations.